Compare stocks

Vivoryon Therapeutics N.V. is a clinical-stage biotechnology company specializing in the development of small molecule medicines targeting post-translational modifications implicated in various diseases. Its lead candidate, varoglutamstat, is an oral inhibitor of glutaminyl cyclases (QPCT and QPCTL) with potential applications in inflammatory and fibrotic diseases, neurodegenerative conditions, and cancer. Originally focused on Alzheimer's disease, the company shifted its strategic emphasis to kidney diseases in 2024 after observing significant improvements in kidney function during clinical trials. Headquartered in Halle (Saale) and Munich, Germany, Vivoryon has expanded its intellectual property portfolio, including a U.S. patent granted in May 2025 for varoglutamstat, providing exclusivity through 2044. The company's unique approach centers on modulating disease-related protein activity and stability through targeted enzyme inhibition.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.